

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0260

TITLE: Experimental Treatment of Prostate Cancer Models with  
Rh2, An Isolated Ginsenoside Compound

PRINCIPAL INVESTIGATOR: Xiaowei S. Xie, Ph.D.

CONTRACTING ORGANIZATION: University of British Columbia  
Vancouver, British Columbia V6T 1Z3  
Canada

REPORT DATE: March 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**BEST AVAILABLE COPY**

**20040901 066**

<b>REPORT DOCUMENTATION PAGE</b>			<b>Form Approved OMB No. 074-0188</b>	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> March 2004	<b>3. REPORT TYPE AND DATES COVERED</b> Annual Summary (15 Mar 2002 - 14 Mar 2004)	
<b>4. TITLE AND SUBTITLE</b> Experimental Treatment of Prostate Cancer Models with Rh2, An Isolated Ginsenoside Compound			<b>5. FUNDING NUMBERS</b> DAMD17-02-1-0260	
<b>6. AUTHOR(S)</b> Xiaowei S. Xie, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of British Columbia Vancouver, British Columbia V6T 1Z3 Canada  <b>E-Mail:</b> sxie@vanhosp.bc.ca			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b> Original contains color plates: All DTIC reproductions will be in black and white.				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> Ginseng is commonly used in herbal preparations for traditional Chinese medicine. Rh2, one of the ginsenosides, has been shown to suppress growth and induce apoptosis in a number of cancer cell lines both in vitro and in vivo. To evaluate the combined efficacy of Rh2 and two chemotherapeutic agents, Paclitaxel and mitoxantrone, mice bearing the LNCaP or PC-3 prostate tumor xenograft were treated with corn oil (po) and saline (iv), Rh2 (50mg/kg po daily), paclitaxel (6 mg/kg iv on day 1, 4, 15, and 18), mitoxantrone (2.5 mg/kg iv on day 1, 4, 15, and 18), Rh2 + paclitaxel and Rh2 + mitoxantrone. Tumor volumes were measured twice weekly for 4 weeks. Serum PSA were tested using ELISA for LNCaP models. Results showed 1) For the LNCaP models, student t-test was performed on the data acquired and results showed statistically significant differences exist between the tumor growth ratio of control group and Rh2+ paclitaxel treatment group (P<0.05) from day 9. No statistical significant differences existed between the control group and the Rh2, paclitaxel or mitoxantrone monotreatment groups. Paclitaxel monotherapy and paclitaxel + Rh2 combination showed significant (p<0.05) and very significant (p<0.01) inhibitory effect on serum PSA levels. 2) There was no statistically significant differences exist between PC-3 model groups treated with placebo, Rh2, Paclitaxel, mitoxantrone or combination. Overall, our results suggest that oral administration of Rh2 can sensitize low dose of Paclitaxel in the treatment of mice bearing subcutaneous LNCaP prostate tumors and exhibits potential as a chemosensitizer of paclitaxel for treatment of androgen-dependent prostate cancer.				
<b>14. SUBJECT TERMS</b> Prostate cancer, tumor xenografts, ginsenoside Rh2, chemotherapy				<b>15. NUMBER OF PAGES</b> 14
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	9
Appendices.....	10

**Annual Summary of Research Project**  
**Experimental Treatment of Prostate Cancer Models with Rh2, an Isolated Ginsenoside Compound**  
**DAMD17-02-1-0260**

Ginsenosides, the major active component in *Panax ginseng*, contains a series of derivatives of the triterpene dammarane attached by sugar moieties. Ginsenoside Rh2 has been reported to induce cell proliferation [1] and induce apoptosis [2-4], inhibit proliferation [5] in various human tumour cells. Previous study conducted in our group also demonstrated that Rh2 could inhibit tumour growth in LNCaP prostate cancer models, when used as a monotreatment. In the research reported here, we studied the combination therapy effect of Rh2 and other chemotherapy reagents in prostate cancer models, both androgen dependent and androgen independent.

1) Original Statement of Work (Copied from the grant proposal):

Task 1. To study the toxicity of Rh2 co-administered with Paclitaxel or mitoxantrone in nude mice. (months 1-3)

Although our previous study showed that Rh2 is well tolerated, it is unknown whether toxicity would occur upon combination of Rh2 with conventional chemotherapeutic agents.

Thirty nude mice will be divided into 6 groups, and vehicle solution, Rh2, Paclitaxel, mitoxantrone, Rh2 + Paclitaxel, Rh2 + mitoxantrone will be administered.

A report will be generated by the end of the toxicity study describing any side effect(s)/toxicity. Daily observational and body weight records will be attached.

Task 2. To compare tumor inhibitory effect of Rh2 *in vivo* (months 3-19)

The efficacy of treatment with Rh2 alone and in combination with conventional therapeutic agents will be examined in the LNCaP and PC-3 prostate tumor model. To limit treatment groups to a manageable size, this part of study will be divided into two sections: efficacy study in androgen-dependent prostate tumor models and efficacy study in androgen-independent prostate tumor models. Sixty nude mice will be used in each study. These will be divided into 6 groups to which vehicle solution, Rh2, Paclitaxel, mitoxantrone, Rh2 + Paclitaxel, Rh2 + mitoxantrone will be administered. Tumor volume and PSA will be recorded weekly. At the end of each study, tumor tissue will be harvested and stored at -80°C until further gene expression analysis.

Task 3. To study the mechanism of action of the tumor inhibitory effects of Rh2. (months 6-24)

- a) The RNA of LNCaP tumors from different treatment/control groups will be prepared using TriZol (LifeTech).
- b) Gene array analysis will be carried out using RNA from treated and untreated tumors *in vivo*. Human EST gene microarray slides will be purchased from OCI, Ontario, CA. Gene array analysis will be carried out in the array facility at The Prostate Centre (see letter of collaboration, Nelson). (months 6-19)
- c) The results of gene array analysis will be interpreted using an online database. A report will be generated following cluster analysis to determine differences in gene expression patterns in tumor tissue following treatment, comparing with untreated tumor tissue. Genes involved in apoptosis and cell survival will be examined to specifically detect any change in their expression levels. (months 20-24)

2) Experiment accomplished:

a. Toxicology study:

- i. The first toxicology study was started on Jun 24, 2002 and terminated on July 10, 2002, due to the severe toxicity showed in mitoxantrone treatment group (Fig. 1). The mice in both mitoxantrone alone and mitoxantrone + Rh2 group lost >15% body weight in 1 week. Treatment was stopped and mice in both groups regained body weight.




Figure 1. Body weight changes of nude mice in toxicology study.

- ii. The second toxicology study was started on July 8, 2002 and terminated on August 5, 2002. Due to the mitoxantrone toxicity showed in the first toxicology study, the mitoxantrone dosage was reduced to 2.5 mg/kg i.v. twice weekly, every other week which is similar to the optimal dosage of mitoxantrone in nude mice reported by Miyake *et al* [6]. Accordingly, Paclitaxel dosage was reduced to 6 mg/kg i.v. twice weekly, every other week.




Figure 2. Body weight changes of nude mice in toxicology study

Based on the findings of the acute toxicity study, we determined that the dosing regime of 6 mg Paclitaxel/kg body weight twice weekly and 2.5 mg mitoxantrone/kg body weight twice weekly are safe in nude mice. The change of dosing regime had been sent to Ms. Cockerham c/o Dr. Nrusingha C. Mishra on 20 June 2002 (see attached copies of email and letter).

b. Efficacy study in nude mice bearing LNCaP prostate tumour xenografts.

Sixty nude mice were purchased and inoculated with LNCaP cells. The tumours achieved 100~150 mm<sup>3</sup> in size by 2<sup>nd</sup> week of October 2002. The treatment started on 18 October 2002. Mice were divided randomly into 6 groups and dosed for 4 weeks as outlined in Table 1.

Table 1. Dose regime for efficacy studies in nude mice bearing LNCaP or PC-3 tumour xenografts.

Group	Corn Oil p.o. (5 days/week)	Rh2 50 mg/kg p.o. (5 days/week)	Saline i.v. (twice/week)	Paclitaxel 6 mg/kg i.v. (twice/week)	Mitoxantrone 2.5 mg/kg i.v. (twice/week)
1	✓		✓		
2		✓	✓		
3	✓			✓	
4	✓				✓
5		✓		✓	
6		✓			✓

For LNCaP models, tumour sizes were measured twice weekly and 100 µl of blood was collected via saphenous vein puncture bleeding. The serum PSA were measured using an ELISA kit (Clinpro, Union City, CA, USA).




Fig. 3. Tumour growth ratio for Rh2/Paclitaxel combination therapy. From day 9, the group treated with Rh2+Paclitaxel showed significant suppression with control group (Student t-test,  $p < 0.05^*$ ).




Fig. 4. Tumour growth ratio for Rh2/Mitoxantrone combination therapy




Fig. 5. The PSA value of different treatment groups. On day 24, the serum PSA of Paclitaxel treatment group showed significant difference with that of control group (Student t-test,  $p < 0.05^*$ ) and the serum PSA of Paclitaxel+Rh2 treatment group showed very significant difference with that of control group (Student t-test,  $p < 0.01^{**}$ ).

c. Efficacy study in nude mice bearing PC-3 prostate tumour xenografts.

Sixty nude mice were purchased and inoculated with PC-3 cells. The tumours achieved 100~130 mm<sup>3</sup> in size by 3<sup>rd</sup> week of April 2004. The treatment started on 24 April 2004. Mice were divided randomly into 6 groups and dosed for 4 weeks as outlined in Table 1. Although mitoxantrone and mitoxantrone/Rh2 combination groups showed the trend of tumour growth inhibition (Fig. 7), there was no significant difference observed.




Fig. 6. Tumour growth ratio for Rh2/Paclitaxel combination therapy.





Fig. 7. Tumour growth ratio for Rh2/Mitoxantrone combination therapy.

d. Tissue Micro Array (TMA) construction and histochemistry staining studies.

Specific aim 3 (gene array analysis for the gene expression pattern change for the tumour cells in the treatment groups) was suggested to be removed by the grant reviewer and thus the fund has not been provided for such study. Alternatively, the novel TMA technology (provided by the pathology core of Prostate Centre at Vancouver General Hospital, headed by Dr. Martin Gleave) was used to analyze the possible cancer related proteins/antigens expression pattern change. In brief, the nude mice bearing LNCaP tumour xenografts from the efficacy study were sacrificed at the end of the study and tumour tissue were collected and fixed. A 312-core TMA was constructed and 100 slides were produced from the tissue block. Various antibodies had been used for the histochemistry staining. An image database had been generated using both manual microscope image capture and Bliss System. Due to the novelty of this technology, the automatic histochemistry score system is not



available yet. All the results are pending score by in-house pathologist. Fig 8 demonstrates one of the TMA slides stained using H&E staining.



### Key Research Accomplishments

- 1) Acute toxicity study showed that 4-week treatment with Rh2 (50 mg/kg p.o. 5 days/week) + Paclitaxel (6 mg/kg i.v. twice weekly) or mitoxantrone (2.5 mg/kg i.v. twice weekly) is safe for nude mice;
- 2) Efficacy study conducted in nude mice bearing LNCaP xenografts showed that Paclitaxel+Rh2 treatment significantly inhibits tumour growth *in vivo* (Student t-test,  $p < 0.05$ ) and significantly inhibits serum total PSA levels (Student t-test,  $p < 0.01$ ).
- 3) Though the efficacy study conducted in nude mice bearing PC-3 xenografts showed no significant differences between different treatment regimes.

### Reportable Outcomes

Abstract 2699: Chemosensitization of Paclitaxel by ginsenoside Rh2: LNCaP tumor growth suppression *in vivo*. 2003 Proceedings of the American Association for Cancer Research. 94<sup>th</sup> AACR Annual Meeting in Toronto, Ontario, Canada. Session EXPERIMENTAL/MOLECULAR THERAPEUTICS 25. (see attachment)

A manuscript is under revision and will be submitted to *Molecular Cancer Therapeutics* by the end of May 2004.

Multiple pharmacokinetics and efficacy study in different tumour models is undergoing, based on the results reported here. After the summary of all the studies, the possibility of clinical trial using the combination of Rh2 and chemotherapeutic agents (e.g. paclitaxel/docetaxel) will be reviewed.

### Conclusion

Low dose Paclitaxel (6 mg/kg i.v. twice weekly) combined with ginsenoside Rh2 (50 mg/kg p.o. 5 days per week) has been proved to be safe and effective therapeutic regime in LNCaP prostate tumour models. Ginsenoside Rh2 sensitizes the tumour inhibitory effects of low dose of Paclitaxel in this androgen-dependent prostate tumour model.

## REFERENCE


1. Zeng, X.L. and Z.G. Tu, *In vitro induction of differentiation by ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line*. Pharmacol Toxicol, 2003. **93**(6): p. 275-83.
2. Ham, Y., et al., *SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis*. Biochemical and Biophysical Research Communications., 2003. **304**(2): p. 358-64.
3. Fei, X., et al., *Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells*. Acta Pharmacologica Sinica., 2002. **23**(4): p. 315-22.
4. Kim, Y., et al., *Ginsenoside Rh2 induces apoptosis independently of Bcl-2, Bcl-xL, or Bax in C6Bu-1 cells*. Archives of Pharmacal Research., 1999. **22**(5): p. 448-53.
5. Oh, M., et al., *Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells*. International Journal of Oncology., 1999. **14**(5): p. 869-75.
6. Miyake, H., et al., *Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model*. British Journal of Cancer., 2001. **84**(6): p. 859-63.

## APPENDICES

1. U.S. Army Medical Research and Materiel Command Animal Use Report for fiscal year 2002;
2. U.S. Army Medical Research and Materiel Command Animal Use Report for fiscal year 2003.

# U.S. Army Medical Research and Materiel Command Animal Use Report

Facility Name: Jack Bell Research Centre  
 Address: 2660 Oak Street  
Vancouver, BC V6H 3Z6  
Canada

Principal Investigator:   
 (Signature)

Principal Investigator: Xiaowei S. Xie  
 (Typed/Printed Name)

Contract Number: DAMD17-02-1-0260

E-mail Address: sxie@vanhosp.bc.ca  
 Phone Number: 604-875-4111 x 63439  
 Fax Number: 604-875-5654

This Report is for Fiscal Year 2003 (01 October 2002 - 30 September 2003)

Definitions of Column Headings on Back of Form					
A. Animal	B. Number of animals purchased, bred, or housed but <b>not</b> yet used	C. Number of animals used involving no pain or distress	D. Number of animals used in which appropriate anesthetic, analgesic, or tranquilizing drugs were used to alleviate pain	E. Number of animals used in which pain or distress was not alleviated	F. Total Number of Animals (Columns C+D+E)
Dogs					
Cats					
Guinea Pigs					
Hamsters					
Rabbits					
Non-human Primates					
Sheep					
Pigs					
Goats					
Horses					
Mice	60	60	N/A	N/A	60
Rats					
Fish					
List Others:					

\*AAALAC - Association for the Assessment and Accreditation of Laboratory Animal Care International

**PURPOSE:** The purpose of this form is to gather data related to animal use for research, development, testing, evaluation, clinical investigations, diagnostic procedures, and/or instructional programs conducted by or for the U.S. Army Medical Research and Materiel Command. This report is **NOT** to be used to report all animals used at your facility unless all work was conducted under contract with the U.S. Army Medical Research and Materiel Command. A separate form must be prepared for each award. This report is to cover one fiscal year (01 October - 30 September).

#### **DEFINITIONS/INSTRUCTIONS:**

Column A: List all animals used for the research, development, testing, evaluation, clinical investigations, diagnostic procedures, and/or instructional programs conducted. For the purpose of this report, an animal is defined as **any living nonhuman vertebrate**.

Column B: Refers to the purchase, breeding, or other acquisition of individual animals in the reporting fiscal year for assignment to a particular work unit or protocol. Animals carried over from the previous fiscal year and not yet used in any procedures or studies, must be included in this number for the work unit or protocol to which they are assigned.

Column C: Number of animals used in which the procedures did not cause more than slight or momentary pain or distress.

Column D: Number of animals used that were given analgesics, anesthetics, or tranquilizers to relieve pain or distress.

Column E: Number of animals used in painful procedures in which pain relieving compounds were not administered.

Column F: Sum of columns C, D, and E.

**Forward this report by DECEMBER 01 of each year to:**

Commander  
U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-RCQ-AR  
504 Scott Street  
Fort Detrick, MD 21702-5012

**Questions should be directed to the office above at 301-619-2144. Completed reports and/or questions may be faxed to this office at 301-619-4165.**

**NOTE: This report may be reproduced.**

# U.S. Army Medical Research and Materiel Command Animal Use Report

Facility Name: Jack Bell Research Centre  
 Address: 2660 Oak Street  
Vancouver, BC V6H 3Z6  
Canada

Principal Investigator:   
 (Signature)

Principal Investigator: Xiaowei S. Xie  
 (Typed/Printed Name)

E-mail Address: sxie@vanhosp.bc.ca

Phone Number: 604-875-4111 x 63439

Fax Number: 604-875-5654

Contract Number: DAMD17-02-1-0260

This Report is for Fiscal Year 2002 (01 October 2001 - 30 September 2002)

Definitions of Column Headings on Back of Form					
A. Animal	B. Number of animals purchased, bred, or housed but <b>not</b> yet used	C. Number of animals used involving no pain or distress	D. Number of animals used in which appropriate anesthetic, analgesic, or tranquilizing drugs were used to alleviate pain	E. Number of animals used in which pain or distress was not alleviated	F. Total Number of Animals (Columns C+D+E)
Dogs					
Cats					
Guinea Pigs					
Hamsters					
Rabbits					
Non-human Primates					
Sheep					
Pigs					
Goats					
Horses					
Mice	120	120	N/A	N/A	120
Rats					
Fish					
List Others:					

\*AAALAC - Association for the Assessment and Accreditation of Laboratory Animal Care International

**PURPOSE:** The purpose of this form is to gather data related to animal use for research, development, testing, evaluation, clinical investigations, diagnostic procedures, and/or instructional programs conducted by or for the U.S. Army Medical Research and Materiel Command. This report is **NOT** to be used to report all animals used at your facility unless all work was conducted under contract with the U.S. Army Medical Research and Materiel Command. A separate form must be prepared for each award. This report is to cover one fiscal year (01 October - 30 September).

**DEFINITIONS/INSTRUCTIONS:**

Column A: List all animals used for the research, development, testing, evaluation, clinical investigations, diagnostic procedures, and/or instructional programs conducted. For the purpose of this report, an animal is defined as **any living nonhuman vertebrate**.

Column B: Refers to the purchase, breeding, or other acquisition of individual animals in the reporting fiscal year for assignment to a particular work unit or protocol. Animals carried over from the previous fiscal year and not yet used in any procedures or studies, must be included in this number for the work unit or protocol to which they are assigned.

Column C: Number of animals used in which the procedures did not cause more than slight or momentary pain or distress.

Column D: Number of animals used that were given analgesics, anesthetics, or tranquilizers to relieve pain or distress.

Column E: Number of animals used in painful procedures in which pain relieving compounds were not administered.

Column F: Sum of columns C, D, and E.

**Forward this report by DECEMBER 01 of each year to:**

Commander  
U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-RCQ-AR  
504 Scott Street  
Fort Detrick, MD 21702-5012

**Questions should be directed to the office above at 301-619-2144. Completed reports and/or questions may be faxed to this office at 301-619-4165.**

**NOTE: This report may be reproduced.**